Articles, Newsletters, Podcasts, and Video

No Unwanted Immune Responses Found for SMA Children on Spinraza

By Steve Bryson PhD / 2023-01-23
Posted in

Spinraza (nusinersen) treatment is safe in children with spinal muscular atrophy (SMA) and does not cause unwanted immune responses, a study confirmed.

The study, involving

more

Ionis Sharing Royalties From Spinraza Sales for $500M Upfront

By Lindsey Shapiro PhD / 2023-01-16
Posted in

In an agreement meant to provide Ionis Pharmaceuticals with additional money to advance potential therapies for various diseases, the company is giving Royalty Pharma a percentage

more

In Real World, Adherence Low to Spinraza Treatment, Data Show

By Steve Bryson PhD / 2023-01-04
Posted in

A significant proportion of people with spinal muscular atrophy (SMA) do not remain on Spinraza (nusinersen) or receive treatment injections as prescribed, according to a

more

Costs of SMA ‘Extremely High’ Prior to Disease-modifying Treatments

By Marisa Wexler MS / 2022-11-30
Posted in

Without disease-modifying treatment (DMT), spinal muscular atrophy (SMA) carries high mortality rates and steep healthcare costs, a study in Hong Kong reported.

Not surprisingly, the

more

Long-term Spinraza Treatment Found to Help SMA Teens, Adults

By Steve Bryson PhD / 2022-11-09
Posted in

Up to 4.5 years of Spinraza (nusinersen) treatment led to meaningful improvements in motor function in adolescents and adults with spinal muscular atrophy (SMA), according

more

Motor Gains Best With Early Use of Spinraza for Likely Type 1 Infants

By Patricia Inacio PhD / 2022-11-07
Posted in

Spinraza (nusinersen) continues to show sustained efficacy in improving motor function in infants and toddlers with spinal muscular atrophy (SMA), according to newly released interim data

more

CHIT1 Immune Protein May Be Marker of Response to Spinraza

By Marisa Wexler MS / 2022-10-17
Posted in

Levels of an immune protein called CHIT1 change over time in children with spinal muscular atrophy (SMA) who undergo treatment with Spinraza (nusinersen), a small

more

Experts Share Insights on Deciding Treatment in Changing Landscape

By Marisa Wexler MS / 2022-10-07
Posted in

Doctors need to be well-educated about options in the evolving treatment landscape to help patients with spinal muscular atrophy (SMA) make informed decisions, say neurologists

more

Better Survival Trends Seen With Spinraza in SMA Children in Sweden

By Marta Figueiredo PhD / 2022-09-02
Posted in

The introduction of Spinraza (nusinersen) as a treatment for spinal muscular atrophy (SMA) in Sweden was associated with trends of improved survival in children diagnosed

more

CADTH: Spinraza Should Not Be Funded for Adults in Canada

By Marisa Wexler MS / 2022-08-31
Posted in

In its final decision, the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended against Spinraza (nusinersen) being reimbursed to treat adults with spinal muscular atrophy (SMA). 

more